Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients

  • Introduction: Over the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for metastatic prostate cancer (mPCa). However, real-world data validating this effect within large-scale epidemiological data sets are scarce. We addressed this void. Materials and Methods: Men with de novo mPCa were identified and systemic chemotherapy status was ascertained within the Surveillance, Epidemiology, and End Results database (2004–2016). Patients were divided between historical (2004–2013) versus contemporary (2014–2016). Chemotherapy rates were plotted over time. Kaplan–Meier plots and Cox regression models with additional multivariable adjustments addressed overall and cancer-specific mortality. All tests were repeated in propensity-matched analyses. Results: Overall, 19,913 patients had de novo mPCa between 2004 and 2016. Of those, 1838 patients received chemotherapy. Of 1838 chemotherapy-exposed patients, 903 were historical, whereas 905 were contemporary. Chemotherapy rates increased from 5% to 25% over time. Median overall survival was not reached in contemporary patients versus was 24 months in historical patients (hazard ratio [HR]: 0.55, p < 0.001). After propensity score matching and additional multivariable adjustment (age, prostate-specific antigen, GGG, cT-stage, cN-stage, cM-stage, and local treatment) a HR of 0.55 (p < 0.001) was recorded. Analyses were repeated for cancer-specific mortality after adjustment for other cause mortality in competing risks regression models and recorded virtually the same findings before and after propensity score matching (HR: 0.55, p < 0.001). Conclusions: In mPCa patients, chemotherapy rates increased over time. A concomitant increase in survival was also recorded.

Download full text files

Export metadata

Metadaten
Author:Robert Benedikt HöhGND, Christoph WürnschimmelORCiD, Rocco S. Flammia, Benedikt Horlemann, Gabriele Sorce, Francesco Chierigo, Zhe Tian, Fred Saad, Markus Graefen, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Derya TilkiORCiDGND, Luis KluthORCiDGND, Philipp Mandel, Felix ChunORCiDGND, Pierre I. Karakiewicz
URN:urn:nbn:de:hebis:30:3-644094
DOI:https://doi.org/10.1002/pros.24235
ISSN:1097-0045
Parent Title (English):The prostate
Publisher:Wiley-Liss
Place of publication:New York, NY
Document Type:Article
Language:English
Date of Publication (online):2021/09/15
Date of first Publication:2021/09/15
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2022/01/12
Tag:chemotherapy; contemporary; metastatic prostate cancer; survival
Volume:81
Issue:16
Page Number:8
First Page:1374
Last Page:1381
Note:
Benedikt Hoeh was awarded a scholarship by the Giersch Stiftung.
HeBIS-PPN:490811817
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0